AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29364329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no comprehensive periodontal treatment)
Number of subjects: 210
Study 26802147 — intervention group
Group type: EXPERIMENTAL
Intervention: mapatumumab-sorafenib (30 mg/kg on day 1 per 21-day cycle)
Number of subjects: 101
Study 26802147 — intervention group
Group type: COMPARATOR
Intervention: placebo-sorafenib (400 mg, twice daily per 21-day cycle)
Number of subjects: 101
Study 26802147 — intervention group
Group type: EXPERIMENTAL
Intervention: mapatumumab-sorafenib
Number of subjects: 101
Study 24469903 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training: three sessions per week, five series of 15 seconds at 30 Hz for 6 months
Number of subjects: 62
Study 24469903 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal daily life
Number of subjects: 62
Study 22559080 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs during the night
Number of subjects: 136
Study 22559080 — intervention group
Group type: COMPARATOR
Intervention: No earplugs during the night (Control)
Number of subjects: 136
Study 20236788 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (verified by exhaled carbon monoxide levels)
Number of subjects: 1504
Study 20236788 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 1504
Study 17639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 64
Study 17639302 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 64
Study 17639302 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Rosiglitazone and Sulfonylurea
Number of subjects: 64
Study 16135471 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (individualized fatigue education and support program delivered in clinic and by phone over three 10- to 20-minute sessions 1 week apart)
Number of subjects: 109
Study 16135471 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 109
Study 12070620 — intervention group
Group type: EXPERIMENTAL
Intervention: 100%G (maximal voluntary contraction for 6 s per set, 12 sets per session)
Number of subjects: 12
Study 12070620 — intervention group
Group type: EXPERIMENTAL
Intervention: 60%G (60% of MVC for 30 s per set, 4 sets per session)
Number of subjects: 12
Study 12070620 — intervention group
Group type: COMPARATOR
Intervention: Both 100%G and 60%G
Number of subjects: 12
Study 9649710 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsies from actinic prurigo patients (UV-induced lesions)
Number of subjects: 10
Study 9649710 — intervention group
Group type: COMPARATOR
Intervention: Skin biopsies from normal individuals (control)
Number of subjects: 10
Study 7673040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-out plastic mask
Number of subjects: 43
Study 7673040 — intervention group
Group type: EXPERIMENTAL
Intervention: Full plastic mask
Number of subjects: 43
Study 7673040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-out Orfit mask
Number of subjects: 43
Study 7673040 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Orfit mask
Number of subjects: 43
Study 7673040 — intervention group
Group type: COMPARATOR
Intervention: Orfit masks
Number of subjects: 43
Study 7673040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-out masks
Number of subjects: 43
Study 7673040 — intervention group
Group type: COMPARATOR
Intervention: Full masks
Number of subjects: 43
Study 2032263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 12
Study 2032263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12
Study 2032263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7362972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocount
Number of subjects: 24
Study 7362972 — intervention group
Group type: COMPARATOR
Intervention: Glucochek
Number of subjects: 24
Study 7362972 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyetone
Number of subjects: 24
Study 7362972 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflomat
Number of subjects: 24
Study 31274388 — intervention group
Group type: EXPERIMENTAL
Intervention: oscillometric ankle-brachial index (oABI)
Number of subjects: 286
Study 31274388 — intervention group
Group type: COMPARATOR
Intervention: Doppler-based ankle-brachial index (dABI)
Number of subjects: 286
Study 31274388 — intervention group
Group type: EXPERIMENTAL
Intervention: pulse wave index (PWI)
Number of subjects: 286
Study 31274388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oABI and PWI
Number of subjects: 286
Study 31274388 — intervention group
Group type: EXPERIMENTAL
Intervention: Time requirement for oABI
Number of subjects: 286
Study 31274388 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for future testing
Number of subjects: 286
Study 28836279 — intervention group
Group type: EXPERIMENTAL
Intervention: Zithromax® (azithromycin)
Number of subjects: 39
Study 28836279 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement without antibiotics (control)
Number of subjects: 39
Study 26785394 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Occupational Therapy
Number of subjects: 762
Study 26785394 — intervention group
Group type: COMPARATOR
Intervention: No Therapy
Number of subjects: 762
Study 24163397 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home assessments
Number of subjects: 57
Study 24163397 — intervention group
Group type: COMPARATOR
Intervention: In-hospital assessments
Number of subjects: 57
Study 24163397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross Motor Function Measure
Number of subjects: 57
Study 24163397 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hammersmith Functional Motor Scale
Number of subjects: 57
Study 24163397 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Test
Number of subjects: 57
Study 24163397 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker
Number of subjects: 57
Study 24163397 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity
Number of subjects: 57
Study 22827885 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention (identification of up to five personal goals in physical activity, cognitive activity, diet and health, and social engagement)
Number of subjects: 75
Study 22827885 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting with mentoring (goal-setting interview followed by bi-monthly telephone mentoring)
Number of subjects: 75
Study 22827885 — intervention group
Group type: COMPARATOR
Intervention: Control (an interview involving a general discussion about the center)
Number of subjects: 75
Study 22827885 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 75
Study 22827885 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting with mentoring
Number of subjects: 75
Study 22827885 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 19082671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 41
Study 19082671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17322803 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 30
Study 17322803 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 30
Study 17322803 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine and 2% lidocaine
Number of subjects: 30
Study 15450559 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg q12h for 5 doses via suppository, followed by oral 250 mg q8h for 6 doses)
Number of subjects: 98
Study 15450559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 11605926 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-garment warming system
Number of subjects: 53
Study 11605926 — intervention group
Group type: COMPARATOR
Intervention: Upper body forced-air warming system
Number of subjects: 53
Study 11605926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 9832480 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA in unstable angina patients with raised baseline levels of CRP, SAA, and IL-6
Number of subjects: 86
Study 9832480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic coronary angiography in unstable angina patients
Number of subjects: 86
Study 9832480 — intervention group
Group type: COMPARATOR
Intervention: PTCA in stable angina patients
Number of subjects: 86
Study 9832480 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic coronary angiography in stable angina patients
Number of subjects: 86
Study 8166478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with thoracic radiotherapy
Number of subjects: 2140
Study 8166478 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2140
Study 2189772 — intervention group
Group type: EXPERIMENTAL
Intervention: Private family practice with study personnel screening
Number of subjects: 576
Study 2189772 — intervention group
Group type: COMPARATOR
Intervention: Academic medical practice with practice receptionist screening
Number of subjects: 576
Study 2189772 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent read by study personnel
Number of subjects: 576
Study 2189772 — intervention group
Group type: COMPARATOR
Intervention: Informed consent read by subjects themselves
Number of subjects: 576
Study 383437 — intervention group
Group type: EXPERIMENTAL
Intervention: carmustin + 5-fluorouracil
Number of subjects: 109
Study 383437 — intervention group
Group type: COMPARATOR
Intervention: carmustin + ftorafur
Number of subjects: 109
Study 31642586 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 411
Study 31642586 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 411
Study 31272568 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese HFpEF patients
Number of subjects: 151
Study 31272568 — intervention group
Group type: COMPARATOR
Intervention: Nonobese HFpEF patients
Number of subjects: 151
Study 29016544 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vibration anesthesia during BTX‐A injections
Number of subjects: 53
Study 29016544 — intervention group
Group type: COMPARATOR
Intervention: Control side (BTX‐A injections only)
Number of subjects: 53
Study 25681059 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (GLPG0634) 10 mg to 200 mg single doses and 300 mg to 450 mg daily doses for 10 days
Number of subjects: 0
Study 23377746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 96
Study 23377746 — intervention group
Group type: COMPARATOR
Intervention: Sodium thiopental
Number of subjects: 96
Study 20663994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0
Study 20663994 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0
Study 19368418 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg/day
Number of subjects: 0
Study 19368418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17299493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (15 mg/day)
Number of subjects: 20
Study 17299493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15074398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 137
Study 15074398 — intervention group
Group type: COMPARATOR
Intervention: Observation (watchful waiting)
Number of subjects: 137
Study 11571763 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 285
Study 11571763 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 36 mg/day
Number of subjects: 285
Study 11571763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 9512200 — intervention group
Group type: EXPERIMENTAL
Intervention: Medi-Jector
Number of subjects: 18
Study 9512200 — intervention group
Group type: COMPARATOR
Intervention: Multidose injection pen
Number of subjects: 18
Study 8148217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg)
Number of subjects: 0
Study 8148217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 0
Study 8148217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg) and Atenolol (100 mg) co-administration
Number of subjects: 0
Study 2659002 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl magnesium glutamate (NAAGA)
Number of subjects: 20
Study 2659002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1168413 — intervention group
Group type: EXPERIMENTAL
Intervention: Alice strain live attenuated influenza A (H3N2) vaccine
Number of subjects: 150
Study 1168413 — intervention group
Group type: COMPARATOR
Intervention: Killed parenteral (KP) bivalent influenza vaccine
Number of subjects: 150
Study 30340960 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral hydration (EOH)
Number of subjects: 0
Study 30340960 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hydration (COH)
Number of subjects: 0
Study 29310386 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity cement (group H, n = 50)
Number of subjects: 100
Study 29310386 — intervention group
Group type: COMPARATOR
Intervention: Low viscosity cement (group L, n = 50)
Number of subjects: 100
Study 26039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope (3.0-mm) with EBUS, fluoroscopy, and virtual bronchoscopic navigation guidance
Number of subjects: 305
Study 26039792 — intervention group
Group type: COMPARATOR
Intervention: Thin bronchoscope with guide sheath (4.0-mm)
Number of subjects: 305
Study 26039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope (3.0-mm)
Number of subjects: 305
Study 23213101 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² bolus followed by 2400 mg/m² 46-hour continuous infusion, once every 2 weeks)
Number of subjects: 342
Study 23213101 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (1,000 mg/m² weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks)
Number of subjects: 342
Study 23213101 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342
Study 23213101 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX and gemcitabine
Number of subjects: 342
Study 20079597 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint chair
Number of subjects: 10
Study 20079597 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 10
Study 19887477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d anastrozole
Number of subjects: 75
Study 19887477 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/wk tamoxifen
Number of subjects: 75
Study 19887477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anastrozole and tamoxifen
Number of subjects: 75
Study 19887477 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 75
Study 16400057 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean ferritin (140 microg Fe as ferritin, 2.5 mg)
Number of subjects: 16
Study 16400057 — intervention group
Group type: COMPARATOR
Intervention: FeSO4 (140 microg Fe as FeSO4, 2.5 mg)
Number of subjects: 16
Study 14718117 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (group A) at 70 (22) W, total work 8050 (2882) kJ
Number of subjects: 35
Study 14718117 — intervention group
Group type: COMPARATOR
Intervention: Low intensity training (group B) at 35 (10) W, total work 4044 (1205) kJ
Number of subjects: 35
Study 11421999 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion of rilmenidine
Number of subjects: 9
Study 11421999 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion of rilmenidine
Number of subjects: 9
Study 11421999 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 9347381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine-lithium therapy
Number of subjects: 12
Study 9347381 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine monotherapy
Number of subjects: 12
Study 8482046 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol (0.5 g/kg body weight diluted to 300 ml in sugar-free orange juice)
Number of subjects: 10
Study 8482046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8482046 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol (0.5 g/kg body weight diluted to 300 ml in sugar-free orange juice) during head-up tilt
Number of subjects: 10
Study 8482046 — intervention group
Group type: COMPARATOR
Intervention: Placebo during head-up tilt
Number of subjects: 10
Study 3087252 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of cromolyn
Number of subjects: 10
Study 3087252 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of cromolyn
Number of subjects: 10
Study 3087252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30587221 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery.
Number of subjects: 386
Study 30587221 — intervention group
Group type: COMPARATOR
Intervention: Stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines.
Number of subjects: 386
Study 27404058 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls on the Go! program (10-week intervention)
Number of subjects: 122
Study 24524222 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 24524222 — intervention group
Group type: COMPARATOR
Intervention: Formoterol monotherapy
Number of subjects: 0
Study 24524222 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 0
Study 24524222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22624298 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of iron
Number of subjects: 17
Study 22624298 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of iron in refined palm oil
Number of subjects: 17
Study 22624298 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of iron in palm oil with CTCMC (two doses)
Number of subjects: 17
Study 22624298 — intervention group
Group type: COMPARATOR
Intervention: Control (without active supplementation)
Number of subjects: 17
Study 20171424 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine 5 mg
Number of subjects: 48
Study 20171424 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine racemate 10 mg
Number of subjects: 48
Study 18394874 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 10mg iv with midazolam-alfentanil sedation
Number of subjects: 120
Study 18394874 — intervention group
Group type: COMPARATOR
Intervention: Placebo with midazolam-alfentanil sedation
Number of subjects: 120
Study 18394874 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 10mg iv with midazolam-alfentanil sedation (in subgroup)
Number of subjects: 120
Study 16160499 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete MoisturePlus
Number of subjects: 31
Study 16160499 — intervention group
Group type: COMPARATOR
Intervention: Opti‐Free Express
Number of subjects: 31
Study 12521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 949
Study 12521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers discontinued
Number of subjects: 949
Study 12521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of beta blockers
Number of subjects: 949
Study 12521629 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of beta blockers
Number of subjects: 949
Study 10807011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic hydroxyethyl starch (HES 6%; 7.2% NaCl)
Number of subjects: 32
Study 10807011 — intervention group
Group type: COMPARATOR
Intervention: Isotonic hydroxyethyl starch (HES 6%; 0.9% NaCl)
Number of subjects: 32
Study 8872324 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 i.v. (VAC)
Number of subjects: 110
Study 8872324 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 10 mg/m2 (VNC)
Number of subjects: 110
Study 1514333 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg
Number of subjects: 17
Study 1514333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6711601 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid therapy
Number of subjects: 2
Study 31425780 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% delgocitinib ointment
Number of subjects: 0
Study 31425780 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% delgocitinib ointment
Number of subjects: 0
Study 31425780 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 0
Study 30368336 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic myofascial release techniques
Number of subjects: 75
Study 30368336 — intervention group
Group type: COMPARATOR
Intervention: Placebo techniques
Number of subjects: 75
Study 26795209 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (5 mg/kg)
Number of subjects: 250
Study 26795209 — intervention group
Group type: COMPARATOR
Intervention: RP (5 mg/kg)
Number of subjects: 250
Study 24556513 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA-Fastrach™
Number of subjects: 80
Study 24556513 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q(®)
Number of subjects: 80
Study 22729307 — intervention group
Group type: EXPERIMENTAL
Intervention: Subxyphoid pleural drain
Number of subjects: 40
Study 22729307 — intervention group
Group type: COMPARATOR
Intervention: Intercostal pleural drain
Number of subjects: 40
Study 19889249 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (40% carbohydrate, 30% protein, 30% fat)
Number of subjects: 36
Study 19889249 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 36
Study 19889249 — intervention group
Group type: COMPARATOR
Intervention: Both diets (A and B)
Number of subjects: 36
Study 16877461 — intervention group
Group type: EXPERIMENTAL
Intervention: New footwear design (intervention group)
Number of subjects: 80